Publicaciones en las que colabora con Gregory Y.H. Lip (24)

2023

  1. Imaging in atrial fibrillation: A way to assess atrial fibrosis and remodeling to assist decision-making

    American Heart Journal, Vol. 258, pp. 1-16

  2. Molecular mechanisms of postoperative atrial fibrillation in patients with obstructive sleep apnea

    FASEB Journal, Vol. 37, Núm. 6

2022

  1. Anthropometric Measures and Risk of Cardiovascular Disease: Is there an Opportunity for Non-Traditional Anthropometric Assessment? A Review

    Reviews in Cardiovascular Medicine, Vol. 23, Núm. 12

  2. Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry

    European Journal of Internal Medicine, Vol. 99, pp. 45-56

  3. Clinical complexity and impact of the ABC (Atrial fibrillation Better Care) pathway in patients with atrial fibrillation: a report from the ESC-EHRA EURObservational Research Programme in AF General Long-Term Registry

    BMC Medicine, Vol. 20, Núm. 1

  4. Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry

    Europace, Vol. 24, Núm. 5, pp. 721-728

  5. Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 7

  6. Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 6

2021

  1. Gut microbiota and the quality of oral anticoagulation in vitamin K antagonists users: A review of potential implications

    Journal of Clinical Medicine, Vol. 10, Núm. 4, pp. 1-16

  2. Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry

    BMC Medicine, Vol. 19, Núm. 1

2018

  1. Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated “Real-World” in Patients With Atrial Fibrillation

    American Journal of Cardiology, Vol. 122, Núm. 5, pp. 785-792

2017

  1. Efficacy of non-vitamin-K antagonist oral anticoagulants for intracardiac thrombi resolution in nonvalvular atrial fibrillation

    Drug Discovery Today, Vol. 22, Núm. 10, pp. 1565-1571

2016

  1. miRNA-197 and miRNA-223 and cardiovascular death in coronary artery disease patients

    Annals of Translational Medicine

2015

  1. A comprehensive insight of novel antioxidant therapies for atrial fibrillation management

    Drug Metabolism Reviews, Vol. 47, Núm. 3, pp. 388-400

  2. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation

    Revista Espanola de Cardiologia, Vol. 68, Núm. 6, pp. 497-504

  3. Effects of body mass index on the lipid profile and biomarkers of inflammation and a fibrinolytic and Prothrombotic state

    Journal of Atherosclerosis and Thrombosis, Vol. 22, Núm. 6, pp. 610-617

2014

  1. High-sensitivity troponin t as a biomarker for the development of atrial fibrillation after cardiac surgery

    European Journal of Cardio-thoracic Surgery, Vol. 45, Núm. 4, pp. 733-738

  2. Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy

    QJM, Vol. 107, Núm. 8, pp. 613-621

2013

  1. Role of microRNAs in cardiac remodelling: New insights and future perspectives

    International Journal of Cardiology, Vol. 167, Núm. 5, pp. 1651-1659

  2. Small-size circulating microparticles in acute coronary syndromes: Relevance to fibrinolytic status, reparative markers and outcomes

    Atherosclerosis, Vol. 227, Núm. 2, pp. 313-322